CLINICAL EVALUATION OF TRIPLE AND QUADRUPLE HELICOBACTER PYLORI ERADICATION THERAPY IN PEPTIC ULCER PATIENTS WITH DIFFERENT ABO BLOOD GROUP PHENOTYPES
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i7.24692Keywords:
Peptic ulcer disease, ABO phenotype, Helicobacter pylori eradication therapyAbstract
Objective: This study aimed to examine the pathological changes in gastric mucosa of Helicobacter pylori-infected peptic ulcer patients carrying different ABO phenotypes and to study the response to the 14 days' standard triple therapy and 10 days' quadruple therapy in peptic ulcer patients according to their ABO phenotypes.
Methods: Interventional prospective randomized-controlled open-label study was performed on newly diagnosed patients with PUD. The H. pylori-positive patients were allocated into two major study groups in which they are subdivided according to ABO blood group phenotypes: Group 1 received standard H. pylori eradication triple therapy and Group 2 received standard H. pylori eradication quadruple regimen. Patients were monitored after 2 months for successful H. pylori eradication.
Results: Chronic active gastritis was significantly high in patients carrying blood Group O phenotype (81.25%), while the atrophic gastritis and intestinal metaplasia were significantly high in patients carrying blood Group A phenotype (25.00% and 16.67%), respectively. 14 days' triple therapy showed significantly lower eradication rate in H. pylori-infected peptic ulcer patients carrying blood Group O phenotype (p<0.01), meanwhile higher response was found among patients with blood Group B. 10 days' quadruple therapy produced a significant high eradication rate in H. pylori-infected patients carrying blood Group O than those with blood Group A (p<0.01), but still both showed lower response compared to that in patients carrying blood Group B and AB phenotypes. Elderly patients showed significantly less healing efficacy than younger patients (p<0.01), and the least healing rate was noticed in female patients after both regimens.
Conclusion: Lower eradication rate in H. pylori-infected was noticed in peptic ulcer patients carrying blood Group O mainly than those with other blood groups and particularly those with duodenal Ulceri. 10 days' quadruple therapy showed significant higher eradication rate in H. pylori infection and a better ulcer healing efficacy.
Downloads
References
Sasidharan S, Ghayethry B, Ravichandran M, Latha LY, Lachumy SJ, Khoo ML, et al. Prevalence of Helicobacter pylori infection among patients referred for endoscopy: Gender and ethnic differences in Kedah, Malaysia. Asian Pac J Trop Dis 2012;2:55-9.
Javed M, Amin K, Muhammad D, Husain A, Mahmood N. Prevalence of H. pylori. Prof Med 2010;17:431-9.
Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014;19 Suppl 1:1-5.
Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC.Systematic review of the epidemiology of complicated peptic ulcer disease: Incidence, recurrence, risk factors and mortality. Digestion 2011;84:102-13.
Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
Enaganti S. Peptic ulcer disease-the disease and non-drug treatment. Hosp Pharm 2006;13:239-43.
Rubin R, Strayer DS. Pathology: Clinicopathologic Foundations of Medicine. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 622-6.
Garratty G. Blood groups and disease: A historical perspective. Transfus Med Rev 2000;14:291-301.
Kutaif RH, Al Mulla Hummadi YM, Najeeb AA. H. pylori infection according to ABO phenotype and Rh factor among Iraqi patienta with PUD. Word J Pharm Res 2015;4:173-86.
Najeeb ST, Mushtaq A. Relationship between blood groups and ulcers: Revisiting the pioneer work. J Pak Med Assoc 2012;62:1367.
Valliani A, Khan F, Chagani B, Khuwaja AK, Majid S, Hashmi S, et al. Factors associated with Helicobacter pylori infection, results from a developing country-Pakistan. Asian Pac J Cancer Prev 2013;14:53-6.
Martins LC, de Oliveira Corvelo TC, Oti HT, do Socorro Pompeu Loiola R, Aguiar DC, dos Santos Barile KA, et al. ABH and Lewis antigen distributions in blood, saliva and gastric mucosa and H pylori infection in gastric ulcer patients. World J Gastroenterol 2006;12:1120 4.
Sharara AL, Abdul-Baki H, El Hajj I, Kreidielh N, Kfoury Baz EM. Association of gasterodudenal diseasephenotype with ABO blood group and Helicobacter pylori virulence specific serotypes. Dig Liver Dis 2006;38:829-33.
Derya CS. Fusun A, Meliha K. The relationship of Helicobacter pylori positivity with age, sex, and ABO/Rhesus blood groups in patients with gasterointestinal complaints in Turkey. Helicobacter 2007;12:244-50.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34 42.
Keramati MR, Sadeghian MH, Ayatollahi H, Badiee Z, Shakibayi H, Moghimi-Roudi A, et al. Role of the Lewis and ABO blood group antigens in Helicobacter pylori infection. Malays J Med Sci 2012;19:17 21.
Mattos DE, Cintra JR, de Mattos CC, Nakashima F, Silva RC, Moreira HW, et al. ABO blood groups and Helicobacter pylori cagA infection: Evidence of an association. J Venom Toxins Ins Trop Dis 2010;17:87-95.
Belda S, Saez J, Santibáñez M, RodrÃguez JC, Sola-Vera J, Ruiz GarcÃa M, et al. Relationship between bacterial load, morbidity and cagA gene in patients infected by Helicobacter pylori. Clin Microbiol Infect 2012;18:E251-3.
Jaff MS. Higher frequency of secretor phenotype in O blood group-its benefits in prevention and/or treatment of some diseases. Int J Nanomed 2010;5:901-5.
Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von willebrand factor levels: From biology to clinical implications. Thromb J 2007;5:14.
Masoodi M, Panahian M, Rezadoost A, Heidari A. Eradication rate of Helicobacter pylori using a two-week quadruple therapy: A Report from southern Iran. Middle East J Dig Dis 2013;5:81-5.
De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012;3:68-73.
Egan BJ, Katicic M, O’Connor H, O’Morain CA. Treatment of Helicobacter pylori infection. Helicobacter 2007;12:31-7.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F, et al. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
Pandit V, Suresh S, Joshi HH. Peptic ulcer and its management. J Pharm Res 2008;1:245-52.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Managment of Helicobacter pylori infection-the Maastrict IV/Florence consensus Report. Gut 2012;61:646-64.
O’Connor A, Gisbert J, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2010;15:46-52.
Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014;20:5302-7.
Tepes B, O’Connor A, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012;17 Suppl 1:36 42.
Hussein NR, Robinson K, Atherton JC. A study of age-specific Helicobacter pylori seropositivity rates in Iraq. Helicobacter 2008;13:306-7.
Al-Windi A, Hussain AH, Salih N. Seroprevalence of anti- Helicobacter pylori antibodies in population of Sulaimani governorate/Kurdistan Region/Iraq. J Zankoy Sulaimani A 2013;15:175-85.
Sharara AI, Abdul-Baki H, ElHajj I, Kreidieh N, Kfoury Baz EM. Association of gastroduodenal disease phenotype with ABO blood group and Helicobacter pylori virulence-specific serotypes. Dig Liver Dis 2006;38:829-33.
Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: A cohort study. Am J Epidemiol 2010;172:1280-5.
Abdulridha MK. The relationship between ABO blood group distribution and the incidence of upper gastric and duodenal ulcer in Iraqi patients. Iraqi J Pharm Sci 2013;22:97-103.
Abo-Shadi MA, El-Shazly TA, Al-Johani MS. Clinical, endoscopic, pathological and serological findings of Helicobacter pylori infection in saudi patients with upper gastrointestinal diseases. Br J Med Med Res 2013;3:1109-124.
Jones J, Scott ML, Voak D. Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients transfusion. Medicine 1995;5:171-84.
Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990;322:909-16.
Batista CA, Silva FM, Barbuti RC, Eisig JN, Mattar R, Navarro Rodriguez T, et al. Neither genotype nor the gastric colonization site of Helicobacter pylori are predictive factors for the development of erosive esophagitis in patients with peptic ulcer disease, 1 year after eradication. Arq Gastroenterol 2009;46:204-8.
SAS. Inst. IncStatistical Analysis System, User’s Guide. Statistical. Version 9. 1st ed. Cary. N.C. USA: SAS. Inst. Inc.; 2012.
Wolpin BM, Kraft P, Xu M, Steplowski E, Olsson ML, Arslan AA, et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: Results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2010;19:3140-9.
Lin CW, Chang YS, Wu SC, Cheng KS. Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Jpn J Med Sci Biol 1998;51:13-23.
Jafarzadeh A, Ahmedi-Kahanali J, Bahrami M, Taghipour Z. Seroprevalence of Anti-helicobacter pylori and anti-cagA antibodies among healthy children according to age, sex, ABO blood groups and rh status in south-east of Iran. Turk J Gastroenterol 2007;18:165-71.
Gatti LL, Lábio Rd, Silva LC, Smith Mde A, Payão SL. CagA positive Helicobacter pylori in Brazilian children related to chronic gastritis. Braz J Infect Dis 2006;10:254-8.
Atherton JC. The pathogenesis of Helicobacter pylori-induced gastroduodenal diseases. Annu Rev Pathol 2006;1:63-96.
Oliveira AG, Santos A, Guerra JB, Rocha GA, Rocha AM, Oliveira CA, et al. BabA2 and cagA positive Helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil. J Clin Microbiol 2003;41:3964-6.
Ribeiro ML, Godoy AP, Benvengo YH, Mendonça S, Pedrazzoli J Jr. Clinical relevance of the cagA, vacA and iceA genotypes of Helicobacter pylori in Brazilian clinical isolates. FEMS Immunol Med Microbiol 2003;36:181-5.
Rizzato C, Kato I, Plummer M, Muñoz N, Stein A, Jan van Doorn L, et al. Risk of advanced gastric precancerous lesions in Helicobacter pylori infected subjects is influenced by ABO blood group and cagA status. Int J Cancer 2013;133:315-22.
Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, et al. ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev 2011;20:1665-72.
Abadi ATB. Helicobacter pylori infection in Iran: A new perspective. J Gastroenterol Hepatol Res 2014;3:1181-5.
Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999;96:12778-83.
Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, et al. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem 2011;286:25256-64.
Hassoon WA, Melconian AK, AL-Safar JM. Study the relationship between hemodialysis (HD) patients and their ABO blood grouping as well as screening of hemodialysis access-related bacterial infections. J Biol Sci 2013;5:291.
Shokrzadeh L, Baghaei K, YamaokaY, Shiota S, Mirsattari D, Porhoseingholi A, et al. Prevalence of Helicobacter pylori infection in dyspeptic patients in Iran. Gastroenterol Insights 2012;4:e8.
Sasidharan S, Ghayethry B, Ravichandran M, Latha LY, Lachumy SJ, Leng KM, et al. Prevalence of Helicobacter pylori infection among patients referred for endoscopy: Gender and ethnic differences in Kedah, Malaysia. Asian Pac J Trop Dis 2012;2:55-9.
Smith DF, Prieto PA. Forssmann antigen. In: Roitt IM, Delves PH, editors. Encyclopedia of Immunology. London: Academic Press; 1992. p. 591-2.
Yuzhalin AE, Kutikhin AG. ABO and rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of south-east Siberia. Asian Pac J Cancer Prev 2012;13:5091-6.
Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, et al. Plasma von willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005;11:2166 70.
O’Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von wille brand factor level. Br J Haematol 2002;116:350-6.
Tadege T, Mengistu Y, Desta K, Asrat D. Seroprevalence of Helicobacter pylori infection in and its relationship with ABO blood groups. Ethiop J Health Dev 2005;19:56-60.
Ashwini P, Sumana MN, Shilpa U, Mamatha P, Manasa P, Dhananjaya BL et al. A review on Helicobacter pylori: Its biology, complications and management. Int J Pharm Pharm Sci 2015; S.l.:14 20.
Nwodo EN, Yakubu SE, Jatau ED, Yabaya A. Seroprevalence of Helicobacter pylori infection in patients with gastritis and peptic ulcer disease in Kaduna, Kaduna State, Nigeria. Afri J Basic Appl Sci 2009;1:123-8.
Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007;76:1005-12.
Zhubi B, Baruti-Gafurri Z, Mekaj Y, Zhubi M, Merovci I, Bunjaku I, et al. Helicobacter pylori infection according to ABO blood group among blood donors in Kosovo. J Health Sci 2011;1:83-9.
Hajiani E, Hashemi J, Vosoghi T. Comparison of a 10 day triple and a two-week quadruple therapy in eradicating Helicobacter pylori infection in patients referred to Imam Khomeini hospital clinics Ahwaz, Iran. Jundishapur J Nat Pharm Prod 2008;3:45-52.
Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014;20:699-705.
Leite KR, Darini E, Canavez FC, Carvalho CM, Mitteldorf CA, Camara-Lopes LH, et al. Helicobacter pylori and cagA gene detected by polymerase chain reaction in gastric biopsies: Correlation with histological findings, proliferation and apoptosis. Sao Paulo Med J 2005;123:113-8.
Yasir S, Moin F, Akhtar SM. Frequency of Helicobacter pylori infection on histopathology in patients with dyspepsia. Am J Clin Med Res 2014;2:53-6.
Bayan K, Tuzun Y, Yilmaz S, Dursun M, Canoruc F. Clarifying the relationship between ABO/Rhesus blood group antigens and upper gastrointestinal bleeding. Dig Dis Sci 2009;54:1029-34.
Jaff MS. Relation between ABO blood groups and Helicobacter pylori infection in symptomatic patients. Clin Exp Gastroenterol 2011;4:221 6.
Kanbay M, Gür G, Arslan H, Yilmaz U, Boyacioglu S. The relationship of ABO blood group, age, gender, smoking, and Helicobacter pylori infection. Dig Dis Sci 2005;50:1214-7.
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection-the maastricht III consensus report. Gut 2007;56:772 81.
Fashner J, Gitu AC. Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician 2015;91:236-42.
Hunt R, Fallone C, Veldhuyzan van Zanten S, et al. Canadian Helicobacter study group consensus conference: Update on the management of Helicobacter pylori - An evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004;18:547-54.
Ching SS, Sabanathan S, Jenkinson LR. Treatment of Helicobacter pylori in surgical practice: A randomized trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 2008;14:3855-60.
Abdul Ghani MA, Abdulridh MK, Najeb AA. Response to first- line quadruple and second-linequadruple H pylori eradication therapy in Iraqi patients with peptic ulcer disease. World J Pharm Res 2015;4:2068 83.
Molina-Infante J, Gisbert J. Letter: Bismuth quadruple therapy with Pylera for H. pylori infection. Aliment Pharmacol Ther 2014;40:735-6.
Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of acombination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-7.
Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565-70.
Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007;21:315-24.
Uygun A, Kadayifci A, Polat Z, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori, Turk. J Gastroenterol 2012;23:8-13.
Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802.
Lai YC, Wang TH, Huang SH, Yang SS, Wu CH, Chen TK, et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol 2003;9:1537-40.
Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:1235 43.
Pilotto A, Salles N. Helicobacter pylori infection in geriatrics. Helicobacter 2002;7 Suppl 1:56-62.
Ali ZA, Hummadi YM, Najeeb AA. Triple and quadruple eradication therapy for H. pylori in Iraqi patients with peptic ulcer disease a comparative study. Br J Med Med Res 2015;7:231-40.
Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181:1359 63.
Abbas SH, Abdulridha MK, Najeb AA. Potential benefit of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease. Asian J Pharm Clin Res 2017;10:313-7.
Sivakumar G, Ragini KP, Kumar NS, Sekhar S, Rao C, Ayyanna C. Evaluation of anti-ulcer activity of hydroalcoholic extract of the Terminalia arjuna bark. Int J Pharm Pharm Sci 2012;4:203-5.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
